News
Booming sales of Wegovy powered the company to become Europe's most valuable, but it has lost over $400 billion in market ...
Novo Nordisk is to cut costs as the Wegovy-maker battles competition from rival Eli Lilly and copycat versions of its obesity ...
Impax Asset Management, an investment management company, released its “Impax US Sustainable Economy Fund” second quarter ...
Eli Lilly offers an annual dividend yield of 0.78%. So, how can investors exploit its dividend yield to pocket a regular $500 ...
The FDA says shortages of GLP-1s are over, but many patients are still getting what are essentially copied medications.
Eli Lilly and Company, a pharmaceutical manufacturing facility, will be receiving up to $100 million in performance-based ...
17h
Transworld Skateboarding on MSNFrom Hawaii to Global Podiums—Lilly Erickson Talks Skateboarding, Roots and What's NextLilly Erickson’s journey in skateboarding started in Hawaii with a Target board covered in hearts—now she’s riding for ...
19hon MSN
Eli Lilly is investing up to $4 billion in the Bristol project and Wisconsin plans to provide up to $100 million in ...
While a substantial portion of pipeline assets are externally sourced, many Big Pharmas are tapping into incubators and ...
Findings from a Phase III study highlight the demonstrated action of donanemab-azbt (brand name Kisunla) in slowing the ...
Novo Nordisk faces a critical phase with its obesity drug Wegovy as it confronts competition from Eli Lilly and potential job ...
The market is driving prices on GLP-1 drugs down, and an added benefit is lower spending on food.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results